首页膀胱肿瘤治疗及预后证据详情

Prognostic value of circulating tumor cells in patients with bladder cancer: A meta-analysis

原文: 2021 年 发布于 Front Oncol 39 卷 第 11 期 40-48 浏览量:216次

作者: Jiang H. Gu X. J. Zuo Z. H. Tian G. Liu J. B.

作者单位: Departments of, Department of, Urology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Medical Library, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Amsterdam, Epidemiology & Biostatistics, Amsterdam Public Health, Amsterdam, The Netherlands. Department of, Pathology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

归属分类: 膀胱肿瘤治疗及预后证据

DOI: 10.1016/j.mgene.2020.100848

关键词: Carcinoma Transitional Cell/mortality/surgery Cystectomy Disease-Free Survival Humans Nephroureterectomy Prognosis *Sex Factors Urinary Bladder Neoplasms/*mortality/*surgery Urologic Neoplasms/*mortality/*surgery carcinoma meta-analysis review [publication type] transitional cell urinary bladder neoplasms

文献简介

Prostate and bladder cancer represent the two most frequently diagnosed genito-urinary malignancies. Diet has been implicated in both prostate and bladder cancer. Given their prolonged latency and high prevalence rates, both prostate and bladder cancer represent attractive candidates for dietary preventive measures, including the use of nutritional supplements. Flavonols, a class of flavonoids, are commonly found in fruit and vegetables and are known for their protective effect against diabetes and cardiovascular diseases. Furthermore, a higher dietary intake of flavonols was associated with a lower risk of both bladder and prostate cancer in epidemiological studies. In this systematic review, we gathered all available evidence supporting the anti-cancer potential of selected flavonols (kaempferol, fisetin and myricetin) against bladder and prostate cancer. A total of 21, 15 and 7 pre-clinical articles on bladder or prostate cancer reporting on kaempferol, fisetin and myricetin, respectively, were found, while more limited evidence was available from animal models and epidemiological studies or clinical trials. In conclusion, the available evidence supports the potential use of these flavonols in prostate and bladder cancer, with a low expected toxicity, thus providing the rationale for clinical trials that explore dosing, settings for clinical use as well as their use in combination with other pharmacological and non-pharmacological interventions.

热门文献